Protocols of a diagnostic study and a randomized controlled non-inferiority trial comparing televisits vs standard in-person outpatient visits for narcolepsy diagnosis and care: TElemedicine for NARcolepsy (TENAR).
Care
Diagnosis
Management
Narcolepsy
Quality of life
Sleep disorders
Sleepiness
Telemedicine
Televisit
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
11 May 2020
11 May 2020
Historique:
received:
13
04
2020
accepted:
03
05
2020
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
18
9
2020
Statut:
epublish
Résumé
Narcolepsy is a rare chronic sleep disorder that typically begins in youth. Excessive daytime sleepiness is the main disabling symptom, but the disease is often associated with severe endocrine-metabolic and psychosocial issues, worsened by a long diagnostic delay, requiring a multidisciplinary approach. The scarcity of reference Sleep Centres forces the patient and family to travel for seeking medical consultations, increasing the economic and psychosocial burden of the disease. Growing evidence suggests that Telemedicine may facilitate patient access to sleep consultations and its non-inferiority in terms of patient satisfaction, adherence to treatment, and symptom improvement for sleep disorders. However, Telemedicine clinical and economic benefits for patients with narcolepsy are still unknown. TENAR is a two-part project, including: 1. a cross-sectional study (involving 250 children and adults with suspected narcolepsy) evaluating the accuracy of Teletriage (i.e., a synchronous live interactive sleep assessment through a Televisit) for narcolepsy diagnosis compared to the reference standard; and 2. a two-arm, parallel, open randomized controlled trial (RCT) to demonstrate the non-inferiority of the multidisciplinary care of narcolepsy through Televisits versus standard care. In this RCT, 202 adolescents (> 14 y.o.) and adults with narcolepsy will be randomly allocated (1:1 ratio) either to Televisits via videoconference or to standard in-person outpatient follow-up visits (control arm). The primary outcome is sleepiness control (according to the Epworth Sleepiness Scale). Secondary outcomes are other symptoms control, compliance with treatment, metabolic control, quality of life, feasibility, patient and family satisfaction with care, safety, and disease-related costs. At baseline and at 12 months, patients will undergo neurologic, metabolic, and psychosocial assessments and we will measure primary and secondary outcomes. Primary outcomes will be also measured at 6 months (remotely or in person, according to the arm). TENAR project will assess, for the first time, the feasibility, accuracy, efficacy and safety of Telemedicine procedures applied to the diagnosis and the multidisciplinary care of children and adults with narcolepsy. The study may be a model for the remote management of other rare disorders, offering care access for patients living in areas lacking medical centres with specific expertise. Number of the Tele-multidisciplinary care study NCT04316286. Registered 20 March 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Narcolepsy is a rare chronic sleep disorder that typically begins in youth. Excessive daytime sleepiness is the main disabling symptom, but the disease is often associated with severe endocrine-metabolic and psychosocial issues, worsened by a long diagnostic delay, requiring a multidisciplinary approach. The scarcity of reference Sleep Centres forces the patient and family to travel for seeking medical consultations, increasing the economic and psychosocial burden of the disease. Growing evidence suggests that Telemedicine may facilitate patient access to sleep consultations and its non-inferiority in terms of patient satisfaction, adherence to treatment, and symptom improvement for sleep disorders. However, Telemedicine clinical and economic benefits for patients with narcolepsy are still unknown.
METHODS
METHODS
TENAR is a two-part project, including: 1. a cross-sectional study (involving 250 children and adults with suspected narcolepsy) evaluating the accuracy of Teletriage (i.e., a synchronous live interactive sleep assessment through a Televisit) for narcolepsy diagnosis compared to the reference standard; and 2. a two-arm, parallel, open randomized controlled trial (RCT) to demonstrate the non-inferiority of the multidisciplinary care of narcolepsy through Televisits versus standard care. In this RCT, 202 adolescents (> 14 y.o.) and adults with narcolepsy will be randomly allocated (1:1 ratio) either to Televisits via videoconference or to standard in-person outpatient follow-up visits (control arm). The primary outcome is sleepiness control (according to the Epworth Sleepiness Scale). Secondary outcomes are other symptoms control, compliance with treatment, metabolic control, quality of life, feasibility, patient and family satisfaction with care, safety, and disease-related costs. At baseline and at 12 months, patients will undergo neurologic, metabolic, and psychosocial assessments and we will measure primary and secondary outcomes. Primary outcomes will be also measured at 6 months (remotely or in person, according to the arm).
DISCUSSION
CONCLUSIONS
TENAR project will assess, for the first time, the feasibility, accuracy, efficacy and safety of Telemedicine procedures applied to the diagnosis and the multidisciplinary care of children and adults with narcolepsy. The study may be a model for the remote management of other rare disorders, offering care access for patients living in areas lacking medical centres with specific expertise.
TRIAL REGISTRATION
BACKGROUND
Number of the Tele-multidisciplinary care study NCT04316286. Registered 20 March 2020.
Identifiants
pubmed: 32393279
doi: 10.1186/s12883-020-01762-9
pii: 10.1186/s12883-020-01762-9
pmc: PMC7212602
doi:
Banques de données
ClinicalTrials.gov
['NCT04316286']
Types de publication
Clinical Trial Protocol
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176Subventions
Organisme : Ministero della Salute
ID : RF-2016-02364742
Références
Lancet Neurol. 2013 Nov;12(11):1068-75
pubmed: 24107292
Int J Med Inform. 2013 Aug;82(8):696-701
pubmed: 23529100
J Nerv Ment Dis. 2019 Feb;207(2):84-99
pubmed: 30672873
J Clin Epidemiol. 1998 Nov;51(11):1025-36
pubmed: 9817120
Neurology. 2017 Jul 11;89(2):153-162
pubmed: 28615434
Sleep Med. 2012 Dec;13(10):1293-300
pubmed: 23026503
BMC Public Health. 2010 Apr 23;10:204
pubmed: 20416042
Neurology. 2017 Apr 4;88(14):1358-1365
pubmed: 28258080
J Telemed Telecare. 2019 Jan;25(1):17-25
pubmed: 28990455
Vaccine. 2013 Feb 6;31(8):1246-54
pubmed: 23246544
J Med Internet Res. 2007 May 17;9(2):e14
pubmed: 17513285
Neurol Sci. 2019 Mar;40(3):447-456
pubmed: 30539345
Sleep Med. 2014 May;15(5):502-7
pubmed: 24780133
Pediatr Neurol. 2018 Aug;85:21-32
pubmed: 30190179
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Expert Rev Respir Med. 2017 Sep;11(9):699-709
pubmed: 28621155
Sleep. 2012 Apr 01;35(4):477-81
pubmed: 22467985
Sleep Med. 2017 May;33:30-35
pubmed: 28449902
Am J Respir Crit Care Med. 2018 Jan 1;197(1):12-14
pubmed: 28926279
Am Health Drug Benefits. 2017 Jul;10(5):233-241
pubmed: 28975007
J Telemed Telecare. 2016 Jun;22(4):209-14
pubmed: 26253747
Mult Scler. 2014 Aug;20(9):1224-33
pubmed: 24436456
Med Care. 1999 Feb;37(2):126-39
pubmed: 10024117
Nat Rev Neurol. 2019 Sep;15(9):519-539
pubmed: 31324898
J Clin Sleep Med. 2015 Oct 15;11(10):1187-98
pubmed: 26414983
J Sleep Res. 2013 Oct;22(5):482-95
pubmed: 23496005
Chest. 2016 Jun;149(6):1556-65
pubmed: 26970035
BMC Psychiatry. 2007 Feb 06;7:7
pubmed: 17284321
J Am Acad Child Adolesc Psychiatry. 1997 Apr;36(4):554-65
pubmed: 9100431
Sleep Med. 2020 Feb;66:110-118
pubmed: 31841742
Sleep. 2002 Mar 15;25(2):193-6
pubmed: 11902428
Neurol Sci. 2003 Feb;23(6):295-300
pubmed: 12624716
J Clin Sleep Med. 2016 Mar;12(3):401-7
pubmed: 26518705
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571